分组1 - InspireMD, Inc. reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.22, representing an earnings surprise of +36.36% [1] - The company posted revenues of $3.15 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 14.93%, and showing a year-over-year increase from $1.95 million [2] - InspireMD has surpassed consensus revenue estimates four times over the last four quarters, indicating a positive trend in revenue performance [2] 分组2 - The stock has added about 0.6% since the beginning of the year, while the S&P 500 has declined by 1.9%, suggesting relative outperformance [3] - The current consensus EPS estimate for the upcoming quarter is -$0.22 on revenues of $2.42 million, and for the current fiscal year, it is -$0.82 on revenues of $15.19 million [7] - The Medical - Instruments industry, to which InspireMD belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable industry outlook [8]

分组1 - Wheaton Precious Metals Corp. reported quarterly earnings of $1.22 per share, exceeding the Zacks Consensus Estimate of $0.93 per share, and showing a significant increase from $0.44 per share a year ago, resulting in an earnings surprise of +31.07% [1] - The company achieved revenues of $864.71 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 31.14%, and up from $380.52 million in the same quarter last year [2] - Wheaton Precious Metals has consistently outperformed consensus EPS estimates over the last four quarters, achieving this four times [2] 分组2 - The stock has increased approximately 26.5% since the beginning of the year, contrasting with a 1% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $1.02 on revenues of $709.82 million, while for the current fiscal year, the estimate is $4.18 on revenues of $3.03 billion [7] - The Mining - Miscellaneous industry, to which Wheaton Precious Metals belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Core Viewpoint - Ollie's Bargain Outlet reported fourth-quarter results that met profit expectations but slightly missed revenue forecasts, while providing a full-year outlook that exceeded market expectations [1][2][3] Financial Performance - Adjusted earnings per share for the fourth quarter were $1.39, compared to analyst expectations of $1.41 [1] - Revenue increased by 17% year over year to $779.25 million, falling short of the consensus estimate of $783.71 million [1] - Adjusted EBITDA for the quarter reached $127.13 million, with a gross margin reported at 39.9% [2] Comparable Store Sales - Comparable store sales rose by 3.6% in the quarter, up from 2.8% a year earlier, driven by larger basket sizes and higher transaction volumes [2] - Strongest category performance during the period included seasonal products, consumables, hardware, stationery, and sporting goods [2] Future Outlook - For fiscal 2026, adjusted earnings per share are expected to be between $4.40 and $4.50, exceeding the analyst consensus estimate of $3.91 [3] - Net sales are projected to range from $2.99 billion to $3.01 billion, above the $2.65 billion forecast by analysts [3] - Comparable store sales growth is anticipated to be about 2%, with a gross margin of approximately 40.5% for the year [3]

Core Insights - CuriosityStream Inc. reported a quarterly loss of $0.06 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, marking an earnings surprise of -71.43% [1] - The company generated revenues of $19.2 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 4.33% and showing an increase from $14.13 million year-over-year [2] - CuriosityStream shares have declined approximately 17.1% since the beginning of the year, contrasting with the S&P 500's decline of 0.9% [3] Earnings Outlook - The earnings outlook for CuriosityStream is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.02 on revenues of $16.47 million, and for the current fiscal year at -$0.02 on revenues of $76.45 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Film and Television Production and Distribution industry, to which CuriosityStream belongs, is currently ranked in the bottom 24% of over 250 Zacks industries, suggesting potential challenges ahead [8]

分组1 - Distribution Solutions Group (DSGR) reported quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.32 per share, and down from $0.42 per share a year ago, representing an earnings surprise of -42.86% [1] - The company posted revenues of $481.6 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 3.09%, and slightly up from year-ago revenues of $480.46 million [2] - Distribution Solutions shares have increased by approximately 8.5% since the beginning of the year, outperforming the S&P 500's gain of 0.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.36 on revenues of $499.2 million, and for the current fiscal year, it is $1.71 on revenues of $2.08 billion [7] - The Zacks Industry Rank indicates that the Industrial Services sector is currently in the bottom 31% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - MSC Industrial, another company in the same industry, is expected to report quarterly earnings of $0.84 per share, reflecting a year-over-year change of +16.7% [9]

分组1 - Merck KGaA reported quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.47 per share, and down from $0.54 per share a year ago, representing an earnings surprise of -40.43% [1] - The company posted revenues of $6.11 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.69%, and up from $5.78 billion year-over-year [2] - Merck KGaA shares have added about 0.4% since the beginning of the year, matching the S&P 500's gain of 0.4% [3] 分组2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Merck KGaA was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is $0.40 on revenues of $5.87 billion, and for the current fiscal year, it is $1.93 on revenues of $24.39 billion [7] 分组3 - The Medical - Drugs industry, to which Merck KGaA belongs, is currently in the top 37% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

分组1 - ChargePoint Holdings, Inc. reported a quarterly loss of $0.54 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.07, representing an earnings surprise of +49.53% [1] - The company posted revenues of $109.32 million for the quarter ended January 2026, exceeding the Zacks Consensus Estimate by 4.51%, and showing an increase from $101.89 million in the same quarter last year [2] - ChargePoint has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed the market, losing about 2.6% since the beginning of the year, compared to a decline of 0.4% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.78 on revenues of $104.75 million, and for the current fiscal year, it is -$3.19 on revenues of $436.25 million [7] - The Automotive - Original Equipment industry, to which ChargePoint belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

分组1 - Cracker Barrel Old Country Store reported quarterly earnings of $0.25 per share, exceeding the Zacks Consensus Estimate of a loss of $0.1 per share, representing an earnings surprise of +343.90% [1] - The company posted revenues of $874.82 million for the quarter ended January 2026, missing the Zacks Consensus Estimate by 2.35%, and a decline from year-ago revenues of $949.44 million [2] - Cracker Barrel shares have increased by approximately 20.9% since the beginning of the year, contrasting with the S&P 500's decline of 0.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.32 on revenues of $790.61 million, and for the current fiscal year, it is -$1.68 on revenues of $3.33 billion [7] - The Zacks Industry Rank for Retail - Restaurants is currently in the bottom 27% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]

分组1 - Verastem reported a quarterly loss of $0.5 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.49, but an improvement from a loss of $1.33 per share a year ago, indicating an earnings surprise of -2.04% [1] - The company generated revenues of $17.54 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.20%, compared to zero revenues in the same quarter last year [2] - Verastem shares have declined approximately 26.4% since the beginning of the year, contrasting with the S&P 500's decline of 0.4% [3] 分组2 - The earnings outlook for Verastem is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.46 on revenues of $22.8 million, and for the current fiscal year at -$1.86 on revenues of $134.45 million [7] - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the bottom 44% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact stock performance [8] - Foghorn Therapeutics Inc., another company in the same industry, is expected to report a quarterly loss of $0.28 per share, with revenues projected to be $8.05 million, reflecting a year-over-year increase of 181.5% [9]

分组1 - Viridian Therapeutics reported a quarterly loss of $1.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.90, and compared to a loss of $0.81 per share a year ago, indicating an earnings surprise of -20.67% [1] - The company posted revenues of $0.13 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 99.29%, and this was an increase from revenues of $0.07 million a year ago [2] - The stock has underperformed the market, losing about 7% since the beginning of the year, while the S&P 500 gained 1.5% [3] 分组2 - The earnings outlook for Viridian Therapeutics is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Viridian Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.98 on $0.1 million in revenues, and for the current fiscal year, it is -$3.50 on $88.07 million in revenues [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Viridian Therapeutics belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8]